使用低剂量帕唑帕尼维持治疗平衡延长生存期与生活质量：与PALETTE研究的比较。
Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
作者信息
Abe Kensaku, Yamamoto Norio, Hayashi Katsuhiro, Takeuchi Akihiko, Miwa Shinji, Inatani Hiroyuki, Higuchi Takashi, Taniguchi Yuta, Tsuchiya Hiroyuki
机构信息
Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
出版信息
Anticancer Res. 2016 Jun;36(6):2893-7.
BACKGROUND
A consensus has not been reached regarding the optimal pazopanib dosing schedule, which we determined in patients who received pazopanib at our Institution.
PATIENTS AND METHODS
Twenty-five patients who were prescribed pazopanib between 2012 and 2015 were included in this retrospective analysis.
RESULTS
The median progression-free survival (PFS) time was 7.7 months. This time (various doses) was similar to that achieved by high-dose pazopanib in the PALETTE study. The log-rank test revealed no significant differences in the PFS times between the low- and high-dose pazopanib groups, with the majority of patients receiving a dose of 400 mg, indicating that controlling the side-effects might be more critical than administering higher doses.
CONCLUSION
Pazopanib should be started from a low dose with careful increase to avoid pazopanib-related side-effects, which is necessary to provide a balance between the life-prolonging effects of pazopanib and quality of life (QoL) of patients.
背景
关于帕唑帕尼的最佳给药方案尚未达成共识，我们在本机构接受帕唑帕尼治疗的患者中确定了该方案。
患者与方法
本回顾性分析纳入了2012年至2015年间接受帕唑帕尼治疗的25例患者。
结果
中位无进展生存期（PFS）为7.7个月。这个时间（不同剂量）与PALETTE研究中高剂量帕唑帕尼所达到的时间相似。对数秩检验显示低剂量和高剂量帕唑帕尼组的PFS时间无显著差异，大多数患者接受400mg剂量，这表明控制副作用可能比给予更高剂量更为关键。
结论
帕唑帕尼应从低剂量开始，并谨慎增加剂量，以避免与帕唑帕尼相关的副作用，这对于在帕唑帕尼的延长生命效果和患者生活质量（QoL）之间取得平衡是必要的。
Zotero 插件